<DOC>
	<DOCNO>NCT01784445</DOCNO>
	<brief_summary>Diclophenac potassium ceftazidime commercially available drug use various clinical situation . They safe know year . Diclophenac potassium Ceftazidime use study prophylaxis treatment pancreatitis Post-ERCP Pancreatitis ( PEP ) . Diclophenac potassium , together indometacin currently standard treatment prevention ( PEP ) ceftazidime possible alternative treatment patient contraindication nonsteroidal medicine . The aim study evaluate efficacy Ceftazidime prophylaxis PEP .</brief_summary>
	<brief_title>Post ERCP Pancreatitis Prevention Average Risk Patients</brief_title>
	<detailed_description>Study type : Interventional Allocation : Randomized Endpoint Classification : Efficacy Study Intervention Model : Parallel Assignment Masking : Investigator Primary Purpose : Prevention Study Phase : Phase 4 Conditions Focus study : Post ERCP pancreatitis Intervention information - Intervention Names ERCP - Arm Information - Arm 1 : Ceftazidime - Arm 2 ( active comparator ) : Diclophenac potassium</detailed_description>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<criteria>All patient undergone ERCP irrespectively diagnosis Unwillingness inability consent study Age &lt; 18 year Previous ERCP ( papillotomy ) Intrauterine pregnancy Breast feeding mother Allergy Aspirin NSAIDs Ceftazidime NSAID antibiotic use within 1 week ( ASA 325 mg daily less acceptable ) Renal failure ( Cr &gt; 1.4 ) Active recent ( within 4 week ) gastrointestinal hemorrhage Existing acute pancreatitis ( lipase peak ) within 72 hour prior ERCP Anticipated inability follow protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Endoscopic Retrograde Cholangiopancreatography ,</keyword>
</DOC>